For APL, down-regulation of both PML-RARα fusion protein and S100A10 are likely responsible for the alleviation of symptoms, such as immoderate fibrinolysis and hemorrhagic complications after the treatment of ATRA. This evidence concerns the gene S100A10 and acute promyelocytic leukemia.